Publication | Closed Access

Treatment of intermediate risk rhabdomyosarcoma and undifferentiated sarcoma with alternating cycles of vincristine/doxorubicin/cyclophosphamide and etoposide/ifosfamide

Surgical OncologyMedicineMetronomic TherapyPathologyUndifferentiated SarcomaIntermediate Risk RhabdomyosarcomaMetronomic ChemotherapyCancer TreatmentOncologyRadiation OncologyCancer Research